Welcome!
Home Feb 22.
Broker's Calls
iX Biopharma remains a 'buy' from PhillipCapital despite $2.8 million net loss in 1H21
PhillipCapital is maintaining its “buy” call on iX Biopharma, but at a lower target price of 44.5 cents.
February 22, 2021